References
- Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocytemia and a high risk of thrombosis. N Engl J Med 1995; 332: 1132–1136
- Randi M L, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica 2005; 90: 261–262
- Harrison C N, Cambell P J, Buck G, Wheatley K, East C L, Bareford D, et al. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33–45
- Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 2007; 21: 277–280
- Birgegard G, Bjorkholm M, Kutti J, Larfars G, Lofvenberg E, Markevarn B, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 2004; 89: 520–527
- Tefferi A, Elliott M A, Kao P C, Yoon S, El-Hemaidi I, Pearson T C. Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera. Blood 2000; 96: 1582–1584
- Carobbio A, Finazzi G, Guerini V, Spinelli O, Delfini F, Marchiali R, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007; 109: 2310–2313